The Medicines Company is a pharmaceutical firm dedicated to improving the treatment of critical care patients by offering innovative and cost-effective medicines to hospitals worldwide. The company's primary product, Angiomax, is an anticoagulant used in conjunction with aspirin for patients undergoing coronary angioplasty. Additionally, The Medicines Company markets Cleviprex, an injectable emulsion for managing blood pressure when oral medications are not suitable. In its development pipeline, the company has two late-stage products: cangrelor, an investigational antiplatelet agent, and oritavancin, a semi-synthetic lipoglycopeptide antibiotic. Furthermore, The Medicines Company is exploring a serine protease inhibitor, CU2010, which is currently in early-stage development.
Annovation BioPharma develops pharmaceutical products in the field of anesthesia, sedation, and sleep. The company was incorporated in 2009 and is based in Wayland, Massachusetts.
Tenaxis Medical, Inc. was founded in 2004 and focuses on the development and commercialization of high-performance sealants and anti-adhesion agents. These products are designed specifically for use in vascular and general surgery, addressing critical needs in surgical procedures to enhance patient outcomes and reduce complications. The company's innovative solutions aim to improve the safety and effectiveness of surgical interventions by minimizing issues related to adhesions and ensuring effective sealing in various surgical applications. Through its dedicated efforts, Tenaxis Medical contributes to advancements in surgical technology and patient care.
Rempex Pharmaceuticals, Inc. is a San Diego-based pharmaceutical company focused on the discovery and development of new antibacterial drugs to meet the growing clinical need created by multi-drug resistant bacterial pathogens. The company’s internal development pipeline focuses on combining proprietary formulations, PK/PD strategies and novel potentiating agents with proven antibiotics to overcome or directly inhibit the molecular mechanisms in bacteria responsible for antibiotic resistance.
ProFibrix B.V. is a biotech company founded in 2004 that specializes in the development and marketing of products for the hemostasis and regenerative medicine markets. The company’s primary product, Fibrocaps, is a dry powder topical hemostat and tissue sealant made from a combination of fibrinogen and thrombin, aimed at stopping acute and severe bleeding during surgical procedures or following traumatic injuries. ProFibrix also provides a sterilized single-use delivery device designed to apply Fibrocaps directly to the target tissue, minimizing disruption to the wound. The company’s products leverage human fibrinogen, a natural blood protein, to enhance hemostasis, blood clotting, and tissue repair.
Incline Therapeutics is a privately-held specialty pharmaceutical company that focuses on the development of IONSYS, a fentanyl iontophoretic transdermal system designed for adult inpatients needing opioid pain relief following surgery. The company is dedicated to creating a compact, disposable, needleless Patient-Controlled Analgesia system that facilitates the short-term management of postoperative pain. Incline Therapeutics is backed by prominent life science venture capital firms and is led by a management team with extensive experience in the pharmaceutical and medical device sectors.
ApoA-I Milano
Acquisition in 2009
ApoA-I Milano is a company that was acquired by The Medicines Company in 2009.
Targanta Therapeutics is a biopharmaceutical company dedicated to the development and commercialization of innovative antibiotics aimed at treating serious infections encountered in hospitals and institutional settings. The company focuses on addressing gram-positive bacterial infections, particularly complicated skin and skin structure infections. By concentrating on these critical areas, Targanta Therapeutics seeks to enhance the efficacy of treatment options available for healthcare providers managing severe infections.
Curacyte Discovery GmbH
Acquisition in 2008
Curacyte Discovery GmbH is a biopharmaceutical company which develops selective inhibitors of urokinase-type plasminogen activator.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.